News

Maintenance therapy with lenalidomide and rituximab is safe and feasible for the treatment of patients with mantle cell lymphoma.

The first group of patients in a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor type 2 has finished dosing.

In an interview with Targeted Oncology, Q3 2023 Oncology Icons honoree, Daniel Efiom-Ekaha, MD, FACP, discussed his years of experience in community practice.

Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.

The FDA has approved capivasertib with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.

Michael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.

Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.

In an interview with Targeted Oncology, Maen Hussein, MD, a Q3 2023 Oncology Icons honoree, discusses his path to the community oncology setting and highlights upcoming trends in oncology he feels will improve patient outcomes.

Repotrectinib is now an FDA-approved option for patients with ROS1- positive advanced non-small cell lung cancer.

In a phase 3 trial, concurrently administered durvalumab and platinum-based chemoradiotherapy did not increase progression-free survival in stage III unresectable non–small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

SIRPant-M has been granted orphan drug designation by the FDA for patients with T-cell lymphoma.

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

This award celebrates the outstanding achievements of professionals who have significantly impacted the oncology landscape.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Following the FDA’s denial of a de novo classification request of ProSense, citing concerns about the choice of comparator group used in the ICE3 trial, IceCure is working to identify a more representative comparator group.

Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

The fast track designation granted to SONALA-001 in combination with the INSIGHTEC Exablate 4000 Type-2 Device from the FDA is for the treatment of patients with diffuse intrinsic pontine glioma.

This companion diagnostic tool, which is already approved for use in 5 other cancer types, identifies patients who may be suited for treatment with pembrolizumab.

Pierre Gholam, MD, discusses the phase 3 RATIONALE-301 study of frontline tislelizumab vs sorafenib for patients with hepatocellular carcinoma.

In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.

Julia Rotow, MD, discussed emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation at the 18th Annual New York Lung Cancers Symposium.

A recent study found that CXC chemokine ligand 13 and galectin-9 could be prognostic biomarkers of progression-free survival and treatment response in patients with chronic lymphocytic leukemia.

An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.

Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.

Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.

Survival benefits for immunotherapy doublets outweigh chemotherapy alone in advanced stage PD-L1-negative non-small cell lung cancer.